For Sales: 888.816.4721 | Contact Us

NIH's biomarker consortium releases study data on Alzheimer's

January 11, 2012

NIH’s biomarker consortium releases study data on Alzheimer’s

Health Imaging

January 11, 2012

The Foundation for the National Institutes of Health (FNIH)  Biomarkers Consortium has released biomarker data from  studies intended to improve the ability to diagnose and measure the  progression of Alzheimer’s disease (AD).

Researchers used proteomics to  identify biomarkers for Alzheimer’s disease using cerebrospinal fluid  (CSF) samples provided by the Alzheimer’s Disease Neuroimaging  Initiative (ADNI). As with all ADNI data, these have been made openly available  to the global research community. This Biomarkers Consortium study, “Use of Targeted Multiplex  Proteomic Strategies to Identify CSF-Based Biomarkers in Alzheimer’s  Disease,” represents the second part of a two-phased effort using  samples collected by ADNI to qualify biomarker panels in both plasma and  CSF to diagnose and monitor disease progression in people with  Alzheimer’s.

This study was conducted by a team of researchers from  academia, pharmaceutical companies, the National Institutes of Health  (NIH) and the FDA under the auspices of  the FNIH Biomarkers Consortium, a Bethesda, Md.-based public-private partnership that seeks  to develop biomarkers to expedite the diagnosis and treatment of major  diseases. Additional studies utilizing ADNI CSF samples are also  underway as part of this project.

Launched in 2004, ADNI is a multi-million dollar  study aimed at defining the subtle changes that may take place in the  brains of older people many years before overt AD symptoms appear. It is led by the National Institute on Aging at  NIH, through a grant to the nonprofit Northern California Institute for  Research and Education, with private sector support from organizations provided through the FNIH. The study uses  imaging and biomarkers to identify changes taking place in the brains  of older people with normal cognition, mild cognitive impairment (MCI,  which often leads to Alzheimer’s) and Alzheimer’s dementia. A renewal  of the ADNI effort (ADNI 2) was announced in October 2010 by the FNIH  and the NIA, which will continue ADNI for an additional five years  through late 2015.

In addition to the NIH and FDA, participating and funding  organizations include Alzheimer’s Drug Discovery Foundation, Eisai, Eli Lilly, Janssen Alzheimer Immunotherapy Research  & Development, Merck, Pfizer and Takeda Global  Research and Development Center.